Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 21;2015(5):CD011316.
doi: 10.1002/14651858.CD011316.pub2.

Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids

Kayleigh M Kew  1 , Sean Beggs, Shaleen Ahmad
Affiliations

Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids

Kayleigh M Kew et al. Cochrane Database Syst Rev. .

Abstract

Background: Asthma is the most common chronic medical condition among children and is one of the most common causes of hospitalisation and medical visits. Poorly controlled asthma often leads to preventable exacerbations that require additional medications, hospital stays, or treatment in the emergency department.Long-acting beta2-agonists (LABA) are the preferred add-on treatment for children with asthma whose symptoms are not well controlled on inhaled corticosteroids (ICS). The US Food and Drug Administration has issued a 'black box' warning for LABA in asthma, and now recommends that they be used "for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved".

Objectives: To compare the effect on asthma control and adverse effects of stepping down to inhaled corticosteroids (ICS)-only therapy versus continuing ICS plus LABA in children whose asthma is well controlled on combined ICS and LABA therapy.

Search methods: We searched the Cochrane Airways Group Specialised Register, and also searched www.ClinicalTrials.gov, www.who.int/ictrp/en/, reference lists of primary studies and existing reviews, and manufacturers' trial registries (GlaxoSmithKline and AstraZeneca). We searched all databases from their inception to the present, and imposed no restriction on language of publication. The most recent search was done in April 2015.

Selection criteria: We looked for parallel randomised controlled trials of at least eight weeks' duration, available as published full text, abstract only, or unpublished data. We excluded studies including participants with other chronic respiratory comorbidities (for example bronchiectasis).We looked for studies in which children (18 years or younger) whose asthma was well controlled on any dose of ICS and LABA combination therapy were randomised to: a) step-down therapy to ICS alone or b) continued use of ICS and LABA.We included any dose of LABA (formoterol, salmeterol, vilanterol) and any dose of ICS (beclomethasone, budesonide, ciclesonide, mometasone, flunisolide, fluticasone propionate, fluticasone furoate, triamcinolone) delivered in a combination inhaler or in separate inhalers.

Data collection and analysis: Two review authors independently screened all records identified in the searches. We used a data extraction tool in Microsoft Excel to manage searches and document reasons for inclusion and exclusion, and to extract descriptive and numerical data from trials meeting the inclusion criteria.The prespecified primary outcomes were exacerbations requiring oral steroids, asthma control, and all-cause serious adverse events.

Main results: Despite conducting extensive searches of electronic databases, trial registries and manufacturers' websites we identified no trials matching the inclusion criteria.After removing duplicates, we screened 1031 abstracts, and assessed 43 full-text articles for inclusion. We identified several adult studies, which will be summarised in a separate review (Ahmad 2014). The most common reasons for exclusion after viewing full texts were 'wrong comparison' (n = 22) and 'adult population' (n = 18).Some adult studies recruited adolescents from age 15, but none reported data separately for those under 18.

Authors' conclusions: There is currently no evidence from randomised trials to inform the discontinuation of LABAs in children once asthma control is achieved with ICS plus LABA. It is disappointing that such an important issue has not been studied, and a randomised double-blind trial recruiting children who are controlled on ICS plus LABA is warranted. The study should be large enough to assess children of different ages, and to measure the important safety and efficacy outcomes suggested in this review over at least six months.The only randomised evidence for stopping LABA has been conducted in adults; it will be summarised in a separate review.

PubMed Disclaimer

Conflict of interest statement

Kayleigh Kew: none known

Sean Beggs: none known

Shaleen Ahmad: none known

Figures

1
1
Results of the search and study selection process
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD011316

Similar articles

See all similar articles

Cited by

References

References to studies excluded from this review

Aalbers 2005 {published data only}
    1. Aalbers R, Harris A, Naya I. Adjustable dosing with budesonide/formoterol achieves sustained guideline 'well‐controlled asthma' following step down in treatment [Abstract]. European Respiratory Journal 2005;26:A431.
Berger 2010 {published and unpublished data}
    1. AstraZeneca. A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials.com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726]
    1. Berger WE, Bleecker ER, O'Dowd L, Miller CJ, Mezzanotte W. Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings 2010;31(1):49‐59. - PubMed
Bumbacea 2010 {published data only}
    1. Bumbacea D, Dymek A, Mansikka H. P16 Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently: A randomised controlled trial [Abstract]. Thorax 2010;65((Suppl 4)):A83.
Cowie 2007 {published data only}
    1. Cowie RL, Boulet LP, Keith PK, Scott‐Wilson CA, House KW, Dorinsky PM. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered‐dose inhaler in adolescent and adult patients with persistent asthma: a 52‐week, open‐label, stratified, parallel‐group, multicenter study. Clinical Therapeutics 2007;29(7):1390‐402. - PubMed
FitzGerald 2003 {published data only}
    1. FitzGerald JM, Sears MR, Boulet LP, Becker AB. Erratum: Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: A five month multicentre Canadian study [Canadian Respiratory Journal (2003) vol. 10 (8) (427‐434)]. Canadian Respiratory Journal [Revue canadienne de pneumologie] 2004;11(1):20. - PubMed
    1. FitzGerald JM, Sears MR, Boulet LP, Becker AB, McIvor AR, Ernst P, et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: A five‐month multicentre Canadian study. Canadian Respiratory Journal [Revue canadienne de pneumologie] 2003;10(8):427‐34. - PubMed
Fowler 2002 {published data only}
    1. Fowler SJ, Currie GP, Lipworth BJ, Currie PC. Step‐down therapy with low‐dose fluticasone‐salmeterol combination or medium‐dose hydrofluoroalkane 134a‐beclomethasone alone. Journal of Allergy and Clinical Immunology 2002;109(6):929‐35. - PubMed
Godard 2008 {published and unpublished data}
    1. GlaxoSmithKline. Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long‐acting inhaled 2‐agonist. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014).
    1. Godard P, Attali V. Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]. Proceedings of the American Thoracic Society 2006;3(3):A213.
    1. Godard P, Greillier P, Pigearias B, Nachbaur G, Desfougeres J‐L, Attali V. Maintaining asthma control in persistent asthma: comparison of three strategies in a 6‐month double‐blind randomised study. Respiratory Medicine 2008;102(8):1124‐31. - PubMed
GSK ADA109315 {unpublished data only}
    1. GSK ADA109315. A retrospective study of healthcare utilization and costs of step‐down therapy in asthma patients receiving fluticasone propionate/salmeterol combination. www.gsk‐clinicalstudyregister.com/files2/26012.pdf (accessed 9 December 2014).
GSK SAS40037 {unpublished data only}
    1. GlaxoSmithKline. Randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10 mg Q. www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014).
    1. Oppenheimer J, Stauffer J, Waitkus‐Edwards K, Yancey S, Prillaman B, Sutton L, et al. “Stepping down” from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:J94.
GSK SMS30046 {unpublished data only}
    1. GSK SMS30046. Effects of long‐term administration of salmeterol on clinical symptoms, inhaled corticosteroid requirement and bronchial reactivity, and the effect of stopping long‐term salmeterol treatment. www.gsk‐clinicalstudyregister.com/study/SMS30046#rs (accessed 8 December 2014).
    1. Wilding P, Clark M, Thompson Coon J, Lewis S, Rushton L, Bennett J, et al. Effect of long‐term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 1997;314(7092):1441‐6. - PMC - PubMed
Harrison 1997 {published data only}
    1. Harrison TW, Oborne J, Wilding PJ, Tattersfield AE. A controlled trial of beta2‐agonist dose reduction in asthmatic patients on high doses of beta2‐agonist [Abstract]. European Respiratory Journal 1997;10(Suppl 25):3S.
Ind 2004 {published data only}
    1. Ind PW, Haughney J, Price D, Rosen JP, Kennelly J. Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Respiratory Medicine 2004;98(5):464‐75. - PubMed
Koenig 2008 {published and unpublished data}
    1. Dorinsky P, Stauffer J, Waitkus‐Edwards K, Yancey S, Prillaman B, Sutton L. Stepping down from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control [Abstract]. European Respiratory Journal 2004;24((suppl 48)):309s.
    1. Dorinsky PM, Stauffer J, Waitkus‐Edwards K, Yancey S, Prillaman BA, Sutton L. "Stepping down" from fluticasone propionate/salmeterol 100/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]. Chest 2004;126((4 Suppl)):758S‐a.
    1. GlaxoSmithKline. A multicenter, randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD. www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014).
    1. Koenig S, Waitkus‐Edwards K, Yancey S, Prillaman B, Dorinsky P. Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus are “stepped down” to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy and Clinical Immunology 2004;113(2):S94.
    1. Koenig SM, Ostrom N, Pearlman D, Waitkus‐Edwards K, Yancey S, Prillaman BA, et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped‐down'. Journal of Asthma 2008;45(8):681‐7. - PubMed
Liu 2007 {published data only}
    1. Liu CT, Wang YM, Wang G, Tan CW, Pang YM. A clinical study on the significance of airway hyperresponsiveness monitoring in the adjustment of combined therapy for asthmatic patients. Zhonghua jie he he hu xi za zhi [Chinese Journal of Tuberculosis and Respiratory Diseases] 2007;30(7):498‐503. - PubMed
Nathan 2009 {published data only}
    1. Nathan R, Pearlman D, Nayak A, Nolte H. Safety and tolerability of medium‐dose mometasone furoate/formoterol treatment versus mometasone furoate or formoterol monotherapies in persistent asthmatics who previously used medium‐dose inhaled corticosteroids (alone or with long‐acting beta2‐agonist) [Abstract]. Chest 2009;136(4):8S.
    1. Nathan R, Pearlman D, Nolte H, Nayak A. Safety and tolerability of mometasone furoate/formoterol for persistent asthma subjects who previously were treated with medium‐dose inhaled corticosteroids (alone or with a long‐acting beta2‐agonist) [Abstract]. Annals of Allergy, Asthma & Immunology 2009;103(4):A58.
NCT00158834 {unpublished data only}
    1. NCT00158834. Pediatric asthma study using stepwise treatment with two Food and Drug Administration approved asthma medications. www.clinicaltrials.gov/ct2/show/study/NCT00158834 (accessed 5 December 2014).
NCT01565031 {unpublished data only}
    1. NCT01565031. Prediction of future risk in patients with controlled asthma. https://clinicaltrials.gov/show/NCT01565031 (accessed 9 December 2014).
NCT02094937 {unpublished data only}
    1. NCT02094937. A study to compare the efficacy and safety of fluticasone furoate (FF) 100 mcg once daily with fluticasone propionate (FP) 250 mcg twice daily (BD) and FP 100 mcg BD in well‐controlled asthmatic Japanese subjects. https://clinicaltrials.gov/ct2/show/NCT02094937 (accessed 9 September 2014).
NTR2045 {unpublished data only}
    1. Kersten E. The effect of stepping down asthma therapy in clinically stable children on exercise induced asthma. www.trialregister.nl/trialreg/admin/rctview.asp?TC=2045 (accessed 5 December 2014).
Obase 2013 {published data only}
    1. Obase Y, Ikeda M, Kurose K, Abe M, Shimizu H, Ohue Y, et al. Step‐down of budesonide/formoterol in early stages of asthma treatment leads to insufficient anti‐inflammatory effect. Journal of Asthma 2013;50(7):718‐21. - PubMed
Paggiaro 2011 {published data only}
    1. Paggiaro P, Nicolini G, Crimi N, Fabbri L, Olivieri D, Rossi A, et al. Six months step down treatment from high dose ICS/LABA combination therapy in asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine 2011;183(Meeting Abstracts):A1278.
    1. Paggiaro P, Nicolini G, Crimi N, Fabbri LM, Olivieri D, Rossi A, et al. Asthma control and lung function after step down from high dose ICS/LABA combination therapy [Abstract]. European Respiratory Journal 2011;38(suppl 55):722s [P3967].
Papi 2012 {published data only}
    1. NCT00497237. Prospective, randomised, open‐label, multicentre, active drug controlled, parallel group design clinical trial of the efficacy and safety of beclomethasone dipropionate 400 Mcg + formoterol 24 mcg pMDI via HFA‐134a (Foster™) vs. fluticasone propionate 500 mcg + salmeterol xinafoate 100 mcg DPI (Seretide Diskus®) in the 6 months stepdown treatment of adult patients with controlled asthma. https://clinicaltrials.gov/show/NCT00497237 (accessed 9 December 2014).
    1. Papi A, Nicolini G, Crimi N, Fabbri L, Olivieri D, Rossi A, et al. Step‐down from high dose fixed combination therapy in asthma patients: a randomized controlled trial. Respiratory Research 2012;13:54. - PMC - PubMed
Reddel 2010 {published and unpublished data}
    1. GlaxoSmithKline. A 13‐month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014).
    1. Reddel HK, Gibson PG, Peters MJ, Wark PAB, Sand IB, Hoyos CM, et al. Down‐titration from high‐dose combination therapy in asthma: Removal of long‐acting beta(2)‐agonist. Respiratory Medicine 2010;104(8):1110‐20. - PubMed
    1. Reddel HK, Peyters MJ, Wark PA, Sand IB, Jenkins CR. Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041.
Self 1998 {published data only}
    1. Rumbak M, Self T, Kelso T, Eberle L, Abou‐Shala N, Learned S, et al. Moderate to high dose inhaled corticosteroids in adult asthmatics: does salmeterol facilitate step down therapy? [Abstract]. European Respiratory Journal 1998;12((Suppl 29)):19s.
    1. Self T, Rumbak MJ, Kelso T, Eberle L, Abou Shala N, Learned CC, et al. Does salmeterol facilitate 'step‐down' therapy in patients with asthma receiving moderate to high doses of inhaled corticosteroids?. Current Therapeutic Research, Clinical and Experimental 1998;59(11):803‐11.
Shamsul 2007 {published data only}
    1. Shamsul AI, Hadzri HM, Noradina AT, Fauzi MA, Hamid AJ, Rosalina AM, et al. Step‐down approach in chronic stable asthma; a comparison of reducing dose inhaled formoterol/budesonide with maintaining inhaled budesonide [Abstract]. Respirology 2007;12(s4):A141.
Slankard 2011 {published and unpublished data}
    1. Slankard ML, Canfield S, Michelis M, Mansukhani M, McGoey B, Paige A, et al. ADRB2 (adrenergic B2 receptor agonist gene) Arg 16 allele and effect of LABA withdrawal in patients with moderate to severe asthma [Abstract]. Journal of Asthma and Clinical Immunology (Proceedings of the AAAAI Annual Meeting 2011) 2011;127(2):AB67.
Zangrilli 2009 {published data only}
    1. Zangrilli J, Uryniak T, O'Brien CD. Efficacy of budesonide/formoterol (BUD/FM) vs BUD in Hispanic patients: Differential results when including run‐in lung function vs controller history and run‐in symptoms [Abstract]. Annals of Allergy, Asthma and Immunology 2009;103:5.

References to ongoing studies

NCT01437995 {unpublished data only}
    1. NCT01437995. Long‐acting beta agonist step down study (LASST). Available from http://clinicaltrials.gov/show/NCT01437995 (accessed 10 September 2014).

Additional references

Adams 2005
    1. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Beclomethasone versus placebo for chronic asthma. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD002738.pub2] - DOI - PMC - PubMed
Adams 2009
    1. Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4] - DOI - PubMed
Ahmad 2014
    1. Ahmad S, Kew KM, Normansell R. Stopping long‐acting beta2‐agonists (LABA) for adults with asthma well‐controlled on LABA and inhaled corticosteroids. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD011306] - DOI - PMC - PubMed
Anderson 2005
    1. Anderson HR. Prevalence of asthma. BMJ 2005;330:1037. - PMC - PubMed
Australian Asthma Handbook 2014
    1. National Asthma Council Australia. Australian Asthma Handbook 2014, Version 1.0. www.asthmahandbook.org.au (accessed 28 July 2014). [ISSN: 2203–4722]
Barnes 1993
    1. Barnes PJ, Adcock I. Anti‐inflammatory actions of steroids: molecular mechanisms. Trends in Pharmacological Sciences 1993;14:436‐41. - PubMed
Bijl‐Hofland 2001
    1. Bijl‐Hofland ID, Cloosterman SG, Folgering HT, Elshout FJ, Weel C, Schayck CP. Inhaled corticosteroids, combined with long‐acting beta2‐agonists, improve the perception of bronchoconstriction in asthma. American Journal of Respiratory and Critical Care Medicine 2001;164(5):764‐9. - PubMed
Brown 1983
    1. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta2‐receptor stimulation by circulating epinephrine. The New England Journal of Medicine 1983;309(23):1414‐9. - PubMed
Brozek 2012
    1. Brozek JL, Kraft M, Krishnan JA, Cloutier MM, Lazarus SC, Li JT, et al. Long‐acting ß2‐agonist step‐off in patients with controlled asthma. Archives of Internal Medicine 2012;172(18):1365‐75. - PubMed
BTS 2011
    1. British Thoracic Society. Adult asthma audit report 2011. www.brit‐thoracic.org.uk/audit‐and‐quality‐improvement/ (accessed 9 June 2014).
BTS/SIGN 2012
    1. British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. http://www.brit‐thoracic.org.uk/guidelines/asthma‐guidelines.aspx (accessed 6 June 2014).
Bush 2009
    1. Bush A, Menzies‐Gow A. Phenotypic differences between pediatric and adult asthma. Proceedings of the American Thoracic Society 2009;6(8):712‐9. - PubMed
Cates 2012a
    1. Cates CJ, Cates MJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD006923.pub3] - DOI - PMC - PubMed
Cates 2012b
    1. Cates CJ, Oleszczuk M, Stovold E, Wieland LS. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD010005.pub2] - DOI - PMC - PubMed
Cates 2014
    1. Cates CJ, Wieland LS, Oleszczuk M, Kew KM. Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD010314.pub2] - DOI - PMC - PubMed
Crane 1989
    1. Crane J, Pearce N, Flatt A, Burgess C, Jackson R, Kwong T, et al. Prescribed fenoterol and death from asthma in New Zealand. The Lancet 1989;1(8644):917‐22. - PubMed
Ducharme 2008
    1. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long‐acting beta2‐agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2] - DOI - PMC - PubMed
Ducharme 2010
    1. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long‐acting beta2‐agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2] - DOI - PMC - PubMed
Ernst 2006
    1. Ernst P, McIvor A, Ducharme FM, Boulet LP, Fitzgerald M, Chapman KR, et al. Safety and effectiveness of long‐acting inhaled beta‐agonist bronchodilators when taken with inhaled corticosteroids. Annals of Internal Medicine 2006;146(9):692‐4. - PubMed
FDA 2010
    1. United States Food, Drug Administration. FDA News Release: FDA Announces New Safety Controls for Long‐Acting Beta Agonists, Medications Used to Treat Asthma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200931.htm (accessed 6 May 2015).
GINA 2009
    1. Global Initiative for Asthma. Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger. http://www.ginasthma.org/Global‐Strategy‐for‐the‐Diagnosis‐and‐Managemen... (accessed 28 July 2014).
GINA 2014
    1. Global Initiative for Asthma (GINA). From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf (accessed 19 June 2014).
Global Asthma Report 2011
    1. International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2011. Available from http://www.theunion.org/what‐we‐do/publications/technical/global‐asthma‐... (accessed 4 Aug 2014).
Hernández 2014
    1. Hernández G, Avila M, Pont A, Garin O, Alonso J, Laforest L, et al. Long‐acting beta‐agonists plus inhaled corticosteroids safety: a systematic review and meta‐analysis of non‐randomized studies. Respiratory Research 2014;15:83. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration. www.cochrane‐handbook.org.
Johnston 2009
    1. Johnston SL, Edwards MR. Mechanisms of adverse effects of beta‐agonists in asthma. Thorax 2009;64(9):739‐41. - PubMed
Lemanske 2011
    1. Lemanske RF, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, et al. Step‐up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. The New England Journal of Medicine 2010;362:975‐85. - PMC - PubMed
Lipworth 1997
    1. Lipworth BJ. Airway subsensitivity with long‐acting beta2‐agonists: is there a cause for concern?. Drug Safety 1997;16(5):295‐30. - PubMed
McMahon 2011
    1. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD. Age and risks of FDA‐approved long‐acting β₂‐adrenergic receptor agonists. Pediatrics 2011;128(5):e1147‐54. - PubMed
NAEPP 2007
    1. National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf (accessed 6 June 2014).
NCT01462344
    1. NCT01462344. 6‐month Safety and Benefit Study of ADVAIR in Children 4‐11 Years Old (VESTRI). https://www.clinicaltrials.gov/ct2/show/NCT01462344 (accessed 29 June 2012).
Nelson 1995
    1. Nelson HS. Beta‐adrenergic bronchodilators. The New England Journal of Medicine 1995;333(8):449‐506. - PubMed
Nelson 2006
    1. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The salmeterol multicenter asthma research trial. Chest 2006;129:15‐26. - PubMed
Ni Chroinin 2009
    1. Ni Chroinin M, Lasserson TJ, Greenstone I, Ducharme FM. Addition of long‐acting beta‐agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007949] - DOI - PMC - PubMed
NRAD 2014
    1. Royal College of Physicians. Why asthma still kills: the national review of asthma deaths. https://www.rcplondon.ac.uk/sites/default/files/why‐asthma‐still‐kills‐f... (accessed 28 August 2014).
Oppenheimer 2008
    1. Oppenheimer J, Nelson HS. Safety of long‐acting β‐agonists in asthma: a review. Current Opinion in Pulmonary Medicine 2008;14:64‐9. - PubMed
PHAC 2007
    1. Public Health Agency of Canada. Life and Breath: Respiratory Disease in Canada. http://www.phac‐aspc.gc.ca/ (accessed 28 July 2014).
Pruteanu 2014
    1. Pruteanu AI, Chauhan BF, Zhang L, Prietsch SOM, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: dose‐response effects on growth. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009878.pub2] - DOI - PMC - PubMed
Review Manager 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Salpeter 2006
    1. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta‐analysis: effect of long‐acting beta‐agonists on severe asthma exacerbations and asthma related deaths. Annals of Internal Medicine 2006;144:904‐12. - PubMed
Spycher 2010
    1. Spycher BD, Silverman M, Kuehni CE. Phenotypes of childhood asthma: are they real?. Experimental Allergy 2010;40:1130‐41. - PubMed
Tattersfield 2006
    1. Tattersfield AE. Current issues with beta2‐adrenoceptor agonists: historical background. Clinical Reviews in Allergy and Immunology 2006;31(2‐3):107‐18. - PubMed
Zhang 2011
    1. Zhang L, Axelsson I, Chung M, Lau J. Dose response of inhaled corticosteroids in children with persistent asthma: a systematic review. Pediatrics 2011;127(1):129‐38. - PubMed
Zhang 2014
    1. Zhang L, Prietsch SOM, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: effects on growth. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009471.pub2] - DOI - PMC - PubMed

Publication types

MeSH terms

Substances